Novavax (NVAX) Cost of Revenue (2011 - 2026)

Novavax's Cost of Revenue history runs 10 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 117.46% year-over-year to $30.7 million in Q1 2026; TTM through Mar 2026 was $89.6 million, a 43.15% decrease from a year earlier, with the FY2025 full-year figure at $73.0 million, down 63.97% from the prior year.
• Cost of Revenue improved to $30.7 million in Q1 2026 per NVAX's latest filing, from $22.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $434.6 million in Q3 2022 and bottomed at $14.1 million in Q1 2025.
• The 5-year median for Cost of Revenue is $46.2 million (2024), against an average of $91.3 million.
• Biggest YoY gain for Cost of Revenue was 124.19% in 2023; the steepest drop was 79.42% in 2023.
• Year by year, Cost of Revenue stood at $181.8 million in 2022, then dropped by 14.74% to $155.0 million in 2023, then tumbled by 76.34% to $36.7 million in 2024, then sank by 39.72% to $22.1 million in 2025, then soared by 38.87% to $30.7 million in 2026.
• Per Business Quant, the three latest NVAX Cost of Revenue figures stand at $30.7 million (Q1 2026), $22.1 million (Q4 2025), and $21.5 million (Q3 2025).